Investigator Perspectives on the Current and Future Management
of Newly Diagnosed Ovarian Cancer — Part 1: Our most recent
one-on-one interview with Dr Monk featuring emerging research and
cases from his practice:
Guidelines for germline and somatic BRCA testing in ovarian
cancer (00:00)
Incidence and potential impact of other clinically relevant
genetic abnormalities on clinical decision-making in the front-line
setting (2:52)
Patient selection for neoadjuvant systemic therapy in clinical
practice (5:31)
Bevacizumab as a component of neoadjuvant systemic therapy for
patients with ovarian cancer (7:52)
Clinical approach to patient selection for neoadjuvant
chemotherapy; perspective on optimal schedule and dose of
neoadjuvant regimen (10:47)
Importance of the extent of response to neoadjuvant
chemotherapy in the timing of debulking surgery (13:57)
Therapeutic approach for patients with newly diagnosed ovarian
cancer, germline BRCA mutations, bilateral pleural effusions and
liver metastases (16:17)
Lingering controversies regarding the use of intraperitoneal
chemotherapy for ovarian cancer (18:30)
GOG-0252: Design and results of a Phase III trial of
intravenous or intraperitoneal chemotherapy, each in combination
with bevacizumab, for advanced ovarian cancer (20:40)
Perspective on the recent FDA approval of bevacizumab in
combination with carboplatin and paclitaxel followed by
single-agent bevacizumab for Stage III or IV epithelial ovarian
cancer after initial surgical resection (22:29)
Importance of disease stage and amount of residual disease in
the decision to use bevacizumab as a component of primary therapy
after debulking surgery (25:21)
Evaluating the optimal duration of maintenance bevacizumab
(26:39)
Effect of bevacizumab on progression-free survival for patients
with high-risk disease (28:19)
Risk of bevacizumab-associated gastrointestinal perforation;
contraindications to bevacizumab (29:57)
Perspective on combining a PARP inhibitor with bevacizumab as
maintenance therapy for patients with advanced platinum-sensitive
ovarian cancer (32:15)
PAOLA-1: An ongoing Phase III trial of olaparib combined with
bevacizumab as maintenance therapy for patients with advanced
ovarian cancer after first-line platinum-based chemotherapy in
combination with bevacizumab (35:42)
Practical approaches to mitigating
carboplatin/paclitaxel-induced peripheral neuropathy (36:58)
Comparison of treatment-associated neurotoxicity with
nab paclitaxel and solvent-based paclitaxel
(39:36)
Clinical experience with bevacizumab for ovarian cancer;
management of hypertension and proteinuria (41:08)
Activity and ongoing investigation of anti-angiogenic agents
alone or in combination with PARP inhibitors for advanced ovarian
cancer (42:46)
FDA breakthrough therapy designation for lenvatinib in
combination with pembrolizumab for previously treated advanced
microsatellite instability (MSI)-nonhigh/mismatch repair proficient
endometrial cancer (44:14)
Rationale for the design of ongoing studies combining immune
checkpoint inhibitors with anti-angiogenic agents and/or PARP
inhibitors (45:47)
Modulation of gut microbiome to enhance response to anti-PD-1
immunotherapy; impact of antibiotics on response to treatment with
immune checkpoint inhibitors (49:00)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.